Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients - Results from PRAGUE-19 study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F16%3A00000105" target="_blank" >RIV/61383082:_____/16:00000105 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00090375 RIV/00216208:11110/16:10324392 RIV/00216208:11120/16:43911063 RIV/00064173:_____/16:N0000046

Výsledek na webu

<a href="http://www.internationaljournalofcardiology.com/article/S0167-5273(16)30243-1/abstract" target="_blank" >http://www.internationaljournalofcardiology.com/article/S0167-5273(16)30243-1/abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijcard.2016.02.029" target="_blank" >10.1016/j.ijcard.2016.02.029</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients - Results from PRAGUE-19 study

Popis výsledku v původním jazyce

Several studies have shown early and mid-term safety and feasibility of everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in different clinical settings including patients with ST-elevation myocardial infarction (STEMI) [1], [2] and [3]. Favourable long-term clinical results have been shown in stable patients [4]. Recently, one year clinical follow-up has been presented in STEMI patients with very encouraging results [5] and [6]. On the other hand, the rate of early and mid-term stent thrombosis during dual antiplatelet treatment (DAPT) in this clinical setting is not negligible [5]. Clinical outcome of STEMI patients with implanted BVS after DAPT termination is not known. Thus, we sought to evaluate a 2 year clinical follow-up of patients included in the pilot phase of PRAGUE-19 study with published short-term clinical results.

Název v anglickém jazyce

Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients - Results from PRAGUE-19 study

Popis výsledku anglicky

Several studies have shown early and mid-term safety and feasibility of everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in different clinical settings including patients with ST-elevation myocardial infarction (STEMI) [1], [2] and [3]. Favourable long-term clinical results have been shown in stable patients [4]. Recently, one year clinical follow-up has been presented in STEMI patients with very encouraging results [5] and [6]. On the other hand, the rate of early and mid-term stent thrombosis during dual antiplatelet treatment (DAPT) in this clinical setting is not negligible [5]. Clinical outcome of STEMI patients with implanted BVS after DAPT termination is not known. Thus, we sought to evaluate a 2 year clinical follow-up of patients included in the pilot phase of PRAGUE-19 study with published short-term clinical results.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

INTERNATIONAL JOURNAL OF CARDIOLOGY

ISSN

0167-5273

e-ISSN

—

Svazek periodika

209

Číslo periodika v rámci svazku

15

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

2

Strana od-do

20-21

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—